Research programme: receptor tyrosine kinase inhibitors - Celldex Therapeutics Inc
Latest Information Update: 04 Nov 2017
At a glance
- Originator Kolltan Pharmaceuticals
- Developer Celldex Therapeutics Inc
- Class Small molecules
- Mechanism of Action Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA
- 29 Nov 2016 Kolltan Pharmaceuticals has been acquired and merged into Celldex Therapeutics Inc
- 06 Aug 2013 Receptor tyrosine kinase inhibitors are still in early research stages for Cancer in USA